CYTRX
| WVB Number : USA000034123 | Country : United States of America |
| SIC categorization : BIOLOGICAL PDS,EX DIAGNSTICS (2836) | ISIN : US2328283013 |
| FT categorization : HEALTH CARE (431) | |
| Company status: ACTIVE |
» Corporation Profile :
| Profile in brief: The Company, a biopharmaceutical research and development company, engages in the development of human therapeutics, specializing in oncology. |
|
| Phone : 1 310 826 5648 | Fax : 310 826 6139 |
| Chairman: : STEVEN A. KRIEGSMAN | Auditor : BDO SEIDMAN LLP |
| CEO/Managing Director : STEVEN A. KRIEGSMAN | |
» Company Facts
| Net Profit Margin (%) | 408.00 |
| Operating Margin (%) | 408.00 |
| Return on Assets (%) | 1.13 |
| Return on Equity (%) | 1.39 |
| Employees | 15 |
» Company Financials
| Annual (2010) | |
| Income Statement ('000 USD ) |
|
| Sales/Total Revenue | 100 |
| EBITDA | 212 |
| EBIT | 104 |
| Net Income | 408 |
| Balance Sheet ( '000 USD) |
|
| Total Current Assets | 35,974 |
| Total Assets | 36,697 |
| Current Liabilities | 6,129 |
| Total Liabilities & Debt | 6,129 |
| Total Equity | 30,568 |
| Cash & Flow ( '000 USD) |
|
| Net Income/Staring Line | 408 |
| Cash from Operating | -14,814 |
| Cash from Investing | 10,827 |
| Cash from Financing | 147 |
| Cash & Equivalent Yr End | 26,892 |